The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Choice of HMA for newly diagnosed TP53-mutant AML: a COMMAND registry study
Talha Badar, MD, Mayo Clinic, Rochester, MN, discusses a COMMAND registry analysis comparing azacitidine and decitabine-based regimens for newly diagnosed TP53-mutated acute myeloid leukemia (AML). Dr Badar explains that although decitabine was associated with slightly higher response rates, both agents produced comparable survival outcomes, supporting either hypomethylating agent (HMA) as a reasonable frontline option. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
